VC
EDIT icon

Vivo Capital’s Editas Medicine EDIT Stock Holding History

Vivo Capital’s Portfolio EDIT Stock Details EDIT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$11.5M Buy
+3,555,250
New +$10.4M 1.05% 27

Other funds holding EDIT

TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return
GGI
GordonMD Global Investments Beverely Hills, California $207M AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Vivo Capital's EDIT Position: Q2 2026 in Review

Vivo Capital opened a new position in Editas Medicine (EDIT) in Q2 2026: 3,555,250 shares worth $11.5M. The stake represents 1.05% of the portfolio and ranks #27 among its holdings.

197 funds tracked by Wall St. Rank hold EDIT as of Q2 2026.

  • Vivo Capital held 3,555,250 shares of Editas Medicine worth $11.5M as of Q2 2026.
  • Editas Medicine was a new Vivo Capital position in Q2 2026.
  • Editas Medicine made up 1.05% of Vivo Capital's portfolio in Q2 2026, its #27 holding.
  • 197 funds tracked by Wall St. Rank held Editas Medicine as of Q2 2026.

Based on Vivo Capital's 13F filing for Q2 2026, filed 14 Aug 2026.